Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.92 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006523 | 0.96 | POLB (1.00) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL2331252 | 0.94 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7856315 | 0.94 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7856311 | 0.94 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7854826 | 0.94 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL30701864 | 0.94 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL30701863 | 0.94 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL230157 | 0.91 | POLB (0.84) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL6753946 | 0.91 | NPC1 (0.81) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL856769 | 0.89 | POLB (0.79) | POLBNPC1RAB9ADDAH1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108822130-A | Benzimidazole ring kind and the preparation method and application thereof | 天津师范大学 | 2018-11-16 | — | — | CN | claimed |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-2970074-B1 | HYDROFORMYLATION PROVESS USING A HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-108822130-A | Benzimidazole ring kind and the preparation method and application thereof | 天津师范大学 | 2018-11-16 | — | — | CN | disclosed |
| US-9573870-B2 | Hetereocyclic agent as catalytic stabilizing agent in a hydroformylation process | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2970074-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | Dow Technology Investments LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376101-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC | 2015-12-31 | — | — | US | disclosed |
| WO-2014149915-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-0873292-B1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEM PLASTIC (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-0873292-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5731472-A | HETEROCYCLIC NITROGEN COMPOUNDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997020798-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-06-12 | — | — | WO | disclosed |
| EP-0268553-B1 | PHOTOSENSITIVE MIXTURES | CIBA-GEIGY AG (CH) | 1991-09-11 | — | — | EP | disclosed |
| US-4835085-A | 1,2-Naphthoquinone diazide sulfonyl ester compound with linking benzotriazole groups and light-sensitive composition with compound | CIBA-GEIGY CORPORATION (US) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376101-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | NUDT1, CAT, HRAS | POLB 337/4885NPC1 4091/4885RAB9A 2488/4885 |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | POLB 32/4885NPC1 4654/4885RAB9A 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.